.png)
Antimicrobial therapeutics have extremely high societal value and investing in a strong R&D ecosystem and market offers an opportunity to save thousands of lives in the EU and beyond, reduce the burden of AMR and prevent significant economic damages. Reversing the collapse of the antimicrobial pipeline is not an issue that can be pushed out any further. The EU represents the second largest pharmaceutical market globally and has a significant portion of the remaining antimicrobial R&D infrastructure, it is incumbent on EU institutions and Member States to take decisive actions. In this position paper, co-authored with groups from civil society, we make suggestion, building on previous recommendations from the Council, European Commission and European Parliament to create an ecosystem which can support R&D and access to these vital medicines in the EU and beyond.
Note on endorsements: Only the technical position paper has been formally endorsed by our CSO collaborators. The shorter position paper is a summary of the longer paper created by ARMoR.
